Gold is 2025’s best performer. UBS sees more upside
Investing.com - TD Cowen has raised its price target on IQVIA Holdings (NYSE:IQV) to $206.00 from $168.00 while maintaining a Buy rating on the healthcare data and analytics company. The stock, which has surged over 18% in the past week according to InvestingPro data, currently appears undervalued based on Fair Value analysis.
The research firm cited signs of stabilization in the macro environment, despite ongoing challenges, as a key factor in its decision to increase the price target.
TD Cowen noted that IQVIA has managed to deliver better-than-expected results in its Research and Development Solutions (RDS) segment by focusing on gaining market share, particularly in the biotech sector.
The firm also highlighted IQVIA’s business diversification as a strength, pointing to strong growth in the Technology & Analytics Solutions (TAS) segment, which it expects to continue.
TD Cowen has adjusted its earnings per share estimates for IQVIA to $11.90 for 2025 and $12.86 for 2026, up from previous estimates of $11.80 and $12.71 respectively, with the new price target based on discounted cash flow analysis implying a multiple of approximately 16 times the firm’s 2026 adjusted EPS estimate.
In other recent news, IQVIA Holdings reported impressive financial results for the second quarter of 2025, surpassing earnings expectations. The company achieved earnings per share of $2.81, exceeding the forecasted $2.77, and generated revenue of $4.017 billion, which was higher than the anticipated $3.96 billion. This strong performance was driven by improved demand in the pharmaceutical and biotech sectors, contributing to solid revenues in their Research & Development Solutions segment.
Jefferies raised its price target for IQVIA to $195 from $160, maintaining a Hold rating due to stronger second-quarter bookings, especially in the Evidence-Based Practice segment. Evercore ISI also increased its price target to $220 from $180, citing improved pharma demand and maintaining an Outperform rating. These developments reflect a positive outlook from analysts regarding IQVIA’s performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.